Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
afflict, armed, attack, border, cabinet, campaign, children, civilian, conflict, demonstrated, difficult, East, economic, economy, elderly, feasibility, fourth, Gaza, group, Hezbollah, infiltrated, influence, instability, intensity, interruption, Iran, Islamist, kidnapped, Lebanon, majeure, Middle, military, militia, missile, neighbor, neighboring, OPKO, OXM, Oxyntomodulin, past, political, rocket, situation, small, social, southern, Strip, stroke, Syria, Syrian, threatened, unrest, violence, violent, vivo, war
Removed:
behalf, description, half, macromolecule
Filing tables
Filing exhibits
Related press release
ENTX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002
I, Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:
1. | the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and |
2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 14, 2023 | /s/ Dana Yaacov-Garbeli Dana Yaacov-Garbeli Chief Financial Officer (Principal Financial and Accounting Officer) |